CpG | Position | Genes | p-value | Effect (β) | Previous Studies (ref.)a |
---|
cg03169557 | chr16:89,598,950 | RPL13, SPG7 | 6.59E-09 | 0.0214 | [8, 16,17,18] |
cg05066959 | chr8:41,519,308 | NKX6-3, ANK1, MIR486 | 1.30E-08 | 0.0453 | [6, 8, 9, 16,17,18] |
cg03073402 | chr19:42,927,676 | CNFN, LIPE | 5.59E-08 | -0.0086 | - |
cg22388948 | chr6:82,460,558 | TENT5A | 5.83E-08 | -0.0270 | - |
cg20648333 | chr10:72,298,745 | PALD1, PRF1 | 1.44E-07 | -0.0183 | - |
- Experiment-wide significant CpGs (p < 1.64E-07) in the meta-EWAS ascross three datasets (London-1, London-2, Oxford) using AD case–control status
- aEvidence for implication of same or largely overlapping locus from studies using DNAm assessments in AD-related phenotypes. Annotation of CpGs to specific gene regions was based on the Illumina manifest (v1.0 B5) for the EPIC array and the GREAT annotation tool [28]